Identification and validation of TP53/p53 status as a prognostic marker in penile squamous cell carcinoma: Evidence from a cohort study and meta-analysis

Urologic Oncology: Seminars and Original Investigations · Published 2026-07-24 · DOI 10.1016/j.urolonc.2026.06.002

Authors (11)

Zijian Cai, Hongtao Jin, Yepeng Guo, Desi Chen, Gaowei Huang, Xin Jiang, Jingjin Liu, Bo-nan Chen, Xueqi Zhang, Zhaohui Chen, Zaishang Li

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Cai, Z., Jin, H., Guo, Y., et al. (2026). Identification and validation of TP53/p53 status as a prognostic marker in penile squamous cell carcinoma: Evidence from a cohort study and meta-analysis. Urologic Oncology: Seminars and Original Investigations. https://doi.org/10.1016/j.urolonc.2026.06.002

Related articles

• Therapeutic targeting of TP53 nonsense mutations in cancer · Upsala Journal of Medical Sciences · 2024 · Cites or is cited by this article
• Does size matter? A national analysis of patterns of adjuvant immunotherapy receipt and tumor size–dependent survival in pT3N0M0 clear cell renal cell carcinoma · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Sex-based differences in peri-operative and long-term oncologic outcomes after primary surgical treatment for kidney cancer: A comprehensive analysis from a high-volume tertiary center · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Universally offered germline testing in upper tract urothelial carcinoma · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Automated algorithm for surgical outcomes abstraction for cystectomy · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Post-treatment diffusion MRI–derived apparent diffusion coefficient as a biomarker of response and prognosis following definitive radiotherapy for prostate cancer: Impact of focal dose escalation on ADC dynamics · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Beyond PSA90: Deep PSA response predicts outcomes in nonmetastatic CRPC · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Clinical outcomes of deferred cytoreductive nephrectomy after initial systemic therapy in metastatic renal cell carcinoma: A multicenter retrospective study · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Association of EVITA with safety in advanced urothelial carcinoma: A multicenter real-world study · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal
• Featured SUO Fellow: Parth Thakker, MD · Urologic Oncology: Seminars and Original Investigations · 2026 · Same journal